Pyrimidine Derivatives Targeting nAChRα6 for Dopamine Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for movement disorders and psychiatric conditions associated with dysregulation of dopamine, such as Parkinson's disease, tremor, dystonia, schizophrenia, and addiction, lack effective agents that specifically target the nicotinic acetylcholine receptor α6 (nAChRα6) to modulate dopamine release.
Innovation Solution
Development of specific compounds, including 5-aryl pyrimidine and 6-aryl 1,2,4-triazine amines, which act as nAChRα6 antagonists to inhibit dopamine release, thereby providing therapeutic potential for these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current treatments for movement disorders and psychiatric conditions are used, then general symptom management is achieved, but specific targeting of nAChRα6 to modulate dopamine release is not achieved
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (5-aryl pyrimidine and 6-aryl 1,2,4-triazine amines) that selectively bind to the α6 subunit of nicotinic acetylcholine receptors. This selective binding provides localized action at the specific receptor subtype, achieving both high specificity for nAChRα6 and reliable therapeutic efficacy in treating movement disorders and psychiatric conditions through precise dopaminergic modulation.
2Measurement precision
If nAChRα6 antagonists are developed to specifically inhibit dopamine release, then therapeutic precision is improved, but compound structure complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying key molecular parameters including aromatic ring substituents (R1-R6 groups), linker types (L), and heterocyclic core structures. These controlled parameter modifications allow optimization of receptor binding specificity for nAChRα6 while managing molecular complexity. The structure-activity relationship studies demonstrate how changing these parameters enhances selective antagonism of dopamine release through α6-containing receptors.
Data Source
AI summary
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein in, R1, R2, R3, L and X are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy particularly for use in treating disorders associated with nicotinic acetylcholine receptor α6 (nAChRα6) activity.